Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: A Danish nationwide, population-based cohort study - 14/08/14
Abstract |
Background |
Data on subsequent cancers, prognostic factors for mortality, and causes of death are limited in mycosis fungoides (MF) and parapsoriasis.
Objectives |
To assess subsequent cancers, mortality, and causes of death in MF and parapsoriasis.
Methods |
Using the Danish nationwide population-based registries, we identified 368 MF patients and 582 parapsoriasis patients and compared them with the general Danish population for subsequent cancers, mortality, and causes of death.
Results |
Subsequent cancers were significantly increased in parapsoriasis patients (standardized incidence ratio [SIR], 2.0 [95% confidence interval {CI}, 1.6-2.5]), and a trend was observed in MF (SIR, 1.2 [95% CI, 0.9-1.5]). Mortality was significantly increased in MF (SIR, 2.0 [95% CI, 1.8-2.3]) and parapsoriasis (SIR, 1.3 [95% CI, 1.1-1.5]). Excess mortality from MF was highest during the first 5 years of follow-up, and causes of increased death included both malignant and nonmalignant diseases.
Limitations |
We have no information regarding clinical stage, treatments, and patient lifestyles.
Conclusion |
Patients with parapsoriasis had a significantly increased risk of subsequent cancers and increased mortality. In addition, the highest excess mortality in the MF group was observed during the first 5 years of follow-up, which suggests that MF exists in both an aggressive and a more indolent form.
Le texte complet de cet article est disponible en PDF.Key words : causes of death, cutaneous T-cell lymphoma, mortality, mycosis fungoides, parapsoriasis, subsequent cancers
Abbreviations : CI, CTCL, DCR, ICD, MF, NHL, SIR
Plan
Supported by an unrestricted grant from LINAK A/S and the Aage Bangs Foundation. |
|
Conflicts of interest: None declared. |
Vol 71 - N° 3
P. 529-535 - septembre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?